Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type envelope glycoproteins to elicit neutralizing antibodies

Virology

Volumn 305, Issue 1, 2003, Pages 124-137

  Kim, Young B ^a   Han, Dong P ^a   Cao, Carlos ^a   Cho, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; NEUTRALIZING ANTIBODY; PEPTIDE; PROTEIN; RECOMBINANT PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE DELETION; GENE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; LABORATORY TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; RECEPTOR BINDING; SERUM; VACCINATION; VIRUS ENVELOPE; WILD TYPE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS;

EID: 0037225248     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1727     Document Type: Article

References (67)

1. Back, N. K., Smit, L., De Jong, J. J., Keulen, W., Schutten, M., Goudsmit, J., and Tersmette, M. (1994). An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431-438.
2. Barbas, C. F., 3rd, Bjorling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T. M., Zebedee, S. L., Persson, M. A., Nara, P. L., Norrby, E., and Burton, D. R. (1992). Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89, 9339-9343.
3. Barnett, S. W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J., Wang, S., Mboudjeka, I., Leung, L., Lian, Y., Fong, A., Buckner, C., Ly, A., Hilt, S., Ulmer, J., Wild, C. T., Mascola, J. R., and Stamatatos, L. (2001). The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75, 5526-5540.
4. Beddows, S., Louisirirotchanakul, S., Cheingsong-Popov, R., Easterbrook, P. J., Simmonds, P., and Weber, J. (1998). Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies. J. Gen. Virol. 79, 77-82.
5. Burton, D. R., Barbas, C. F., 3rd, Persson, M. A., Koenig, S., Chanock, R. M., and Lerner, R. A. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137.
6. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, E., Steihm, E. R., Bryson, Y. J., Cao, Y., Moore, J. P., Ho, D. D., and Barbas, C. F. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
7. Cao, J., Sullivan, N., Desjardin, E., Parolin, C., Robinson, J., Wyatt, R., and Sodroski, J. (1997). Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71, 9808-9812.
8. Cheng-Mayer, C., Liu, R., Landau, N. R., and Stamatatos, L. (1997). Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71, 1657-1661.
9. Cho, M. W., Kim, Y. B., Lee, M. K., Gupta, K. C., Ross, W., Plishka, R., Buckler-White, A., Igarashi, T., Theodore, T., Byrum, R., Kemp, C., Montefiori, D. C., and Martin, M. A. (2001). Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75, 2224-2234.
10. Cho, M. W., Lee, M. K., Carney, M. C., Berson, J. F., Doms, R. W., and Martin, M. A. (1998). Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72, 2509-2515.
11. Cho, M. W., Lee, M. K., Chen, C. H., Matthews, T., and Martin, M. A. (2000). Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J. Virol. 74, 9749-9754.
12. Cho, M. W., Teterina, N., Egger, D., Bienz, K., and Ehrenfeld, E. (1994). Membrane rearrangement and vesicle induction by recombinant poliovirus 2C and 2BC in human cells. Virology 202, 129-145.
13. Cordonnier, A., Montagnier, L., and Emerman, M. (1989). Single aminoacid changes in HIV envelope affect viral tropism and receptor binding. Nature 340, 571-574.
14. Davis, D., Stephens, D. M., Willers, C., and Lachmann, P. J. (1990). Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J. Gen. Virol. 71, 2889-2898.
15. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666.
16. Fuerst, T. R., Niles, E. G., Studier, F. W., and Moss, B. (1986). Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83, 8122-8126.
17. Golding, H., D'souza, M. P., Bradac, J., Mathieson, B., and Fast, P. (1994). Neutralization of HIV-1. AIDS Res. Hum. Retroviruses 10, 633-643.
18. Goudsmit, J., Debouck, C., Meloen, R. H., Smit, L., Bakker, M., Asher, D. M., Wolff, A. V., Gibbs, C. J., Jr., and Gajdusek, D. C. (1988). Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85, 4478-4482.
19. Helseth, E., Olshevsky, U., Furman, C., and Sodroski, J. (1991). Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65, 2119-2123.
20. Ho, D. D., Mckeating, J. A., Li, X. L., Moudgil, T., Daar, E. S., Sun, N. C., and Robinson, J. E. (1991). Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65, 489-493.
21. Hoffman, T. L., Labranche, C. C., Zhang, W., Canziani, G., Robinson, J., Chaiken, I., Hoxie, J. A., and Doms, R. W. (1999). Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA 96, 6359-6364.
22. Huang, X., Barchi, J. J., Jr., Lung, F. D., Roller, P. P., Nara, P. L., Muschik, J., and Garrity, R. R. (1997). Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry 36, 10846-10856.
23. Javaherian, K., Langlois, A. J., Larosa, G. J., Profy, A. T., Bolognesi, D. P., Herlihy, W. C., Putney, S. D., and Matthews, T. J. (1990). Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 [published erratum appears in Science 251(4989), 13, 1991]. Science 250, 1590-1593.
24. Johnson, W. E., Morgan, J., Reitter, J., Puffer, B. A., Czajak, S., Doms, R. W., and Desrosiers, R. C. (2002). A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 76, 2075-2086.
25. Kang, C. Y., Nara, P., Chamat, S., Caralli, V., Ryskamp, T., Haigwood, N., Newman, R., and Kohler, H. (1991). Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc. Natl. Acad. Sci. USA 88, 6171-6175.
26. Kim, Y. B., Lee, M. K., Han, D. P., and Cho, M. W. (2001). Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res. Hum. Retroviruses 17, 1715-1724.
27. Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W. C., Terwilliger, E., Dayton, A., Rosen, C., Haseltine, W., and Sodroski, J. (1987). Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237, 1351-1355.
28. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659.
29. Lacasse, R. A., Follis, K. E., Trahey, M., Scarborough, J. D., Littman, D. R., and Nunberg, J. H. (1999). Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 283, 357-362.
30. Lasky, L. A., Nakamura, G., Smith, D. H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T., and Capon, D. J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975-985.
31. Lee, M. K., Heaton, J., and Cho, M. W. (1999). Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate. Virology 257, 290-296.
32. Lee, M. K., Martin, M. A., and Cho, M. W. (2000). Higher western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates. AIDS Res. Hum. Retroviruses 16, 765-775.
33. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373-10382.
34. Lu, S., Wyatt, R., Richmond, J. F., Mustafa, F., Wang, S., Weng, J., Montefiori, D. C., Sodroski, J., and Robinson, H. L. (1998). Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14, 151-155.
35. Mackett, M., Smith, G. Y., and Moss, B. (1985). The construction and characterisation of vaccinia virus recombinants expressing foreign genes. In "DNA Cloning" (D. Rickwood, and B. D. Hames, Eds.), 2nd ed., pp. 191-211. IRL Press, Washington, D.C.
36. Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., Clements, M. L., Dolin, R., Graham, B. S., Gorse, G. J., Keefer, M. C., Mcelrath, M. J., Walker, M. C., Wagner, K. F., Mcneil, J. G., Mccutchan, F. E., and Burke, D. S. (1996). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173, 340-348.
37. Matthews, T. J. (1994). Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 10, 631-632.
38. Mckeating, J. A., Gow, J., Goudsmit, J., Pearl, L. H., Mulder, C., and Weiss, R. A. (1989). Characterization of HIV-1 neutralization escape mutants. AIDS 3, 777-784.
39. Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 9 (Suppl. A), S117-S136.
40. Moore, J. P., Mckeating, J. A., Huang, Y. X., Ashkenazi, A., and Ho, D. D. (1992). Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66, 235-243.
41. Moore, J. P., Sattentau, Q. J., Wyatt, R., and Sodroski, J. (1994). Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68, 469-484.
42. Moore, J. P., and Sodroski, J. (1996). Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70, 1863-1872.
43. Ogert, R. A., Lee, M. K., Ross, W., Buckler-White, A., Martin, M. A., and Cho, M. W. (2001). N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75, 5998-6006.
44. Olshevsky, U., Helseth, E., Furman, C., Li, J., Haseltine, W., and Sodroski, J. (1990). Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64, 5701-5707.
45. Palker, T. J., Clark, M. E., Langlois, A. J., Matthews, T. J., Weinhold, K. J., Randall, R. R., Bolognesi, D. P., and Haynes, B. F. (1988). Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85, 1932-1936.
46. Papandreou, M. J., and Fenouillet, E. (1998). Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain. Virology 241, 163-167.
47. Quinones-Kochs, M. I., Buonocore, L., and Rose, J. K. (2002). Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: Effects on protein function and the neutralizing antibody response. J. Virol. 76, 4199-4211.
48. Reitter, J. N., Means, R. E., and Desrosiers, R. C. (1998). A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4, 679-684.
49. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., and Burton, D. R. (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828.
50. Rusche, J. R., Javaherian, K., Mcdanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A., Gallo, R. C., Arthur, L. O., Fischinger, P. J., et al. (1988). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 [published errata appear in Proc. Natl. Acad. Sci. USA 85(22), 8697, 1988; 86(5), 1667, 1989]. Proc. Natl. Acad. Sci. USA 85, 3198-3202.
51. Sattentau, Q. J., Moulard, M., Brivet, B., Botto, F., Guillemot, J. C., Mondor, I., Poignard, P., and Ugolini, S. (1999). Antibody neutralization of HIV-1 and the potential for vaccine design. Immunol. Lett. 66, 143-149.
52. Schnierle, B. S., Stitz, J., Bosch, V., Nocken, F., Merget-Millitzer, H., Engelstadter, M., Kurth, R., Groner, B., and Cichutek, K. (1997). Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc. Natl. Acad. Sci. USA 94, 8640-8645.
53. Schonning, K., Jansson, B., Olofsson, S., Nielsen, J. O., and Hansen, J. S. (1996). Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218, 134-140.
54. Shibata, R., Maldarelli, F., Siemon, C., Matano, T., Parta, M., Miller, G., Fredrickson, T., and Martin, M. A. (1997). Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176, 362-373.
55. Stamatatos, L., and Cheng-Mayer, C. (1998). An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72, 7840-7845.
56. Steimer, K. S., Scandella, C. J., Skiles, P. V., and Haigwood, N. L. (1991). Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254, 105-108.
57. Sullivan, N., Sun, Y., Li, J., Hofmann, W., and Sodroski, J. (1995). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
58. Thali, M., Furman, C., Ho, D. D., Robinson, J., Tilley, S., Pinter, A., and Sodroski, J. (1992). Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66, 5635-5641.
59. Thali, M., Olshevsky, U., Furman, C., Gabuzda, D., Posner, M., and Sodroski, J. (1991). Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65, 6188-6193.
60. Tilley, S. A., Honnen, W. J., Racho, M. E., Hilgartner, M., and Pinter, A. (1991). A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 142, 247-259.
61. UNAIDS/WHO Report (2001). AIDS Epidemic Update. December 2001. WHO, Zanichelli, Bologna.
62. Vahlne, A., Horal, P., Eriksson, K., Jeansson, S., Rymo, L., Hedstrom, K. G., Czerkinsky, C., Holmgren, J., and Svennerholm, B. (1991). Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition. Proc. Natl. Acad. Sci. USA 88, 10744-10748.
63. Vancott, T. C., Mascola, J. R., Loomis-Price, L. D., Sinangil, F., Zitomersky, N., Mcneil, J., Robb, M. L., Birx, D. L., and Barnett, S. (1999). Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J. Virol. 73, 4640-4650.
64. Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., and Sodroski, J. G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711.
65. Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., and Sodroski, J. (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69, 5723-5733.
66. Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J., Posner, M., and Sodroski, J. (1993). Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67, 4557-4565.
67. Yamshchikov, G. V., Ritter, G. D., Vey, M., and Compans, R. W. (1995). Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 214, 50-58.